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Recent research on biosystems at the nanoscale has created one of the most dynamic science and technology domains at the
confluence of physical sciences, molecular engineering, biology, biotechnology, and medicine. This domain includes better
understanding of living and thinking systems, revolutionary biotechnology processes, synthesis of new drugs and their targeted
delivery, regenerative medicine, neuromorphic engineering, and developing a sustainable environment. Nanobiosystems research
is a priority in many countries and its relevance within nanotechnology is expected to increase in the future. The realisation that
the nanoscale has certain properties needed to solve important medical challenges and cater to unmet medical needs is driving
nanomedical research. The present review explores the significance of nanoscience and latest nanotechnologies for human health.
Addressing the associated opportunities, the review also suggests how to manage far-reaching developments in these areas.
Copyright © 2009 S. Shrivastava and D. Dash. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1. Introduction
Nanotechnology and nanoengineering stand to produce
significant scientific and technological advances in diverse
fields including medicine and physiology. In a broad sense,
they can be defined as the science and engineering involved
in the design, synthesis, characterization, and application of
materials and devices whose smallest functional organization
in at least one dimension is on the nanometer scale, ranging
from a few to several hundred nanometers. A nanometer is
one billionth of a meter or three orders of magnitude smaller
then a micron, roughly the size scale of a molecule itself (e.g.,
a DNA molecule is about 2.5 nm long while a sodium atom
is about 0.2 nm).
The potential impact of nanotechnology stems directly
from the spatial and temporal scales being considered:
materials and devices engineered at the nanometer scale
imply controlled manipulation of individual constituent
molecules and atoms in how they are arranged to form
the bulk macroscopic substrate. This, in turn, means that
nanoengineered substrates can be designed to exhibit very
specific and controlled bulk chemical and physical properties
as a result of the control over their molecular synthesis and
assembly.
For applications to medicine and physiology, these
materials and devices can be designed to interact with cells
and tissues at a molecular (i.e., subcellular) level with a
high degree of functional specificity, thus allowing a degree
of integration between technology and biological systems
not previously attainable. It should be appreciated that
nanotechnology is not in itself a single emerging scientific
discipline but rather a meeting of traditional sciences such
as chemistry, physics, materials science, and biology to bring
together the required collective expertise needed to develop
these novel technologies. The present review explores the
significance of nanoscience and latest nanotechnologies for
human health (Figure 1). Addressing the associated oppor-
tunities, the review also suggests how to manage far-reaching
developments in these areas.
2. Scientific and Application-Oriented Research
Living cells are full of complex and highly functional
“machines” at nanometer scale. They are composed of
macromolecules, including proteins. They are involved in
practically every process in the cell, such as informa-
tion transfer, metabolism, andthe transport of substances.
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Figure 1: Schematic illustration of nanotechnology revolutionizing biomedical sciences.
Nanotechnologies offer new instruments for observing the
operation of these machines at the level of individual
molecules, even in the living cell [1]. Using atomic force
microscopes, it is possible, for example, tomeasure the bond-
ing forces between trigger substances, such as hormones,
and the associated receptor proteins that act as switches
in the cell membrane. Biomolecules can be labelled using
quantum dots. The intense light of a specific wavelength
that these nanocrystals emit enables the path followed by
the biomolecules in the cell to be precisely traced [2].
A great deal of this research is concerned with obtaining
information on basic biochemical and biophysical processes
in healthy and diseased cells. This knowledge can provide
the basis for the development of new prevention strategies
and therapies. Beside this primarily knowledge-broadening
research, research is also underway into numerous possi-
ble applications for nanotechnologies in medicine [3, 4].
Research efforts are particularly intensive in the search
for new methods and tools for imaging [5], sensing [6],
targeted drug [7], and gene delivery systems [8]. More
research is also underway into applications in fields such
as tissue medical implants [9] and disinfection [10–14].
Clinical applications are currently scarce partly because of
stringent safety requirements. Nevertheless, experts expect a
great deal from nanomedicine [15] especially in the longer
term (Figure 2).
3. Diagnostics
The enormous increase in knowledge of the human genome
(genomics) and of expression products, proteins (proteomics),
makes it possible in an increasing number of cases to trace
diseases to abnormalities at the molecular level. In theory,
this gives rise to the possibility of making a diagnosis at
a very early stage—and of possibly starting treatment—
even before the initial symptoms of the disease appear
[16, 17]. Attention in medicine is, therefore, increasingly
focusing on prevention. Neonatal screening (by means of
a heel prick) for metabolic diseases is a good example of
this [18]. The medical profession has an ever increasing
number of technical tools at its disposal for detecting these
molecular biomarkers. It is in this field that the impact of
nanotechnologies will probably be noticed first (within five
years) [15, 19]. The diagnostic research can be conducted in
the laboratory using samples taken from the human body (in
vitro research) but it can also be carried out directly on the
patient (in vivo). This distinction is important because, in
the latter case, the tools/agents have to meet more stringent
requirements.
3.1. In the Laboratory. Research into patients’ genetic mate-
rial (DNA) can be conducted to measure gene expression—
the degree of RNA production—in diseased tissue, or to
ascertain which variant of a particular gene a person has.
Many human genes exist in several forms, which only differ
in a single base pair. These are known as single nucleotide
polymorphisms (SNPs). The corresponding protein variants
may differ from each other in a single amino acid and
then display a considerable difference in functionality. SNPs
are the root of all kinds of genetic disorders and also
affect a person’s sensitivity to chemical substances, including
medicines. This refers to their therapeutic effect as well
as their side effects [20]. Genetic research offers major
possibilities for identifying gene types that predispose a
person to certain diseases and for achieving better matches
between individual patients and the medicines they are
prescribed [21, 22].
DNA chips used for analyzing DNA have been available
for a few years now. They are currently widely used in
scientific, biomedical research but they are rarely used in
clinical practice. The chips comprise an inert support which
carries microarrays of hundreds to thousands of single-
strand DNA molecules with different base sequences. DNA
from a tissue sample that has been labelled with a radioactive
or fluorescent material can be identified on the basis of the
place on the chip where it binds to the chip DNA. The
Dutch Cancer Institute has been using a DNA chip since
2003 to predict the spread of breast tumours on the basis
of gene expression profiles. This information makes it much
easier than it was in the past to determine which patients
would benefit from supplementary chemotherapy after the
tumour has been surgically removed [23, 24]. Similar chips
are being developed for the diagnosis of leukaemias [25, 26]
and mouth and throat tumours [27]. DNA chips and other
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Figure 2: Nanotechnologies in medicine.
biochips were originally an achievement of microtechnology
but miniaturisation is advancing here too, as with computer
chips. Nanotechnologies are also increasingly playing a role
in producing the chips and in increasing their detection
sensitivity and reliability [28–31].
A new nanotechnological analytical method uses quan-
tum dots [5]. DNA in a sample is identified on the basis
of its bonding to DNA molecules of a known composition
embedded in micrometre-sized polymer spheres containing
various mixtures of quantum dots, each of which provides
a unique spectral bar code (colour code) [32]. American
researchers have used this method to study SNPs in genes
that code for enzymes of the cytochrome P450 family which
are involved in the breakdown of substances (including
medicines) in the body [33]. The method is very suitable
for studying large quantities of samples on many SNPs
simultaneously (multiplex analyses).
In theory, the composition of DNA molecules can also
be ascertained by pulling them through nanopores in a
membrane by means of an electric potential difference. The
base sequence can be deduced from the time profile of the
electric current through the pores [34]. Researchers have now
used this method to identify a mutation in an HIV gene that
makes the virus resistant to a particular medicine [35]. If
this method, which is still being developed, can be perfected,
it will result in a much faster way of determining the base
sequence of DNA than has thus far been available. This would
involve having to place hundreds of pores on a chip.
The aforementioned techniques would, in principle, also
be suitable for identifying other biopolymers, such as pro-
teins and carbohydrates. Nevertheless, American researchers
have succeeded in developing a chip to detect prostate cancer.
The chip contains around one hundred cantilever sen-
sors (micrometre-sized, nanometres thick miniscule levers),
which are coated on one side with antibodies to prostate-
specific antigen (PSA), a biomarker for that disease. Bonding
of PSA from a sample placed on the chip bends the can-
tilevers several nanometres, which can be detected optically.
This enables clinically relevant concentrations of PSA to
be measured [36, 37]. Antibodies placed on nanowires can
be used in a similar way to detect viruses, in a blood
sample, for example [38, 39]. The bonding of a single virus
particle to an antibody results in a change in the nanowire’s
electric conductance. The method is extremely sensitive,
which means that an infection can be detected at a very early
stage. It is also suitable for multiplex analyses. Work is also
underway on sensors based on carbon nanotubes, for use in
microarrays [40]. Detection methods based on cantilevers,
nanowires or nanotubes offer the added advantage that it is
not necessary to label the sample.
Labs-on-a-chip are pocket-sized laboratories. They can be
used for analyzing biopolymers and also for research and for
manipulating cells. They are expected to play an important
role in the further development of biosensors for the detec-
tion of pathogenic bacteria [41]. In due course, there will
also be possibilities for point-of-care applications, in which
simple analyses can be made in the general practitioner’s
surgery or in the patients’ homes and carried out by the
patients themselves [42]. Researchers of the University of
Twente are currently working on the development of a lab-
on-a-chip for measuring lithium concentrations in the blood
[43]. A chip of this kind would enable patients who use
psychopharmaceuticals based on lithium to keep the lithium
concentration in their blood at the right level. The ease of
use would be comparable with that of current devices that
enable diabetic patients to measure glucose levels in their
blood. Photonic explorers for bioanalysis with biologically
localised embeddings (PEBBLEs) are a final example. These
sensors are a few hundreds of nanometers in size and
are composed of an inert capsule, made of polymers, for
example, containing an indicator colouring agent that emits
light as soon as a substance being analysed diffuses through
the capsule to the inside and binds with the colouring agent
[44]. PEBBLEs were developed for measuring concentrations
of small ions and molecules—such as ions of hydrogen,
calcium, magnesium and zinc, or glucose—in living cells.
Once the nanocapsules have been introduced into a cell,
their light emission (and cessation of emission) can be
monitored using a microscope. Tools of this kind are useful
when studying certain diseases. For example, an abnormal
zinc balance is a characteristic of brain disorders such as
Alzheimer’s disease and Parkinson’s disease [45].
3.2. In Vivo Diagnostics and Imaging. In the case of in
vivo diagnostics, patients are given contrast agents or radio-
pharmaceuticals. Their specific properties mean that these
agents are useful in imaging pathophysiological changes and
functional changes such as changes in blood flow in cells,
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tissue, and organs. The termmolecular imaging is often used,
as today’s imaging techniques are increasingly concerned
with making molecular biomarkers of disease processes
visible, for instance, a receptor protein on the surface of
a cancer cell. To this end, beside being given a contrast
agent (the imaging component), a carrier molecule or
particle is also given a molecule that specifically binds to the
biomarker, such as an antibody (the targeting component).
Various techniques have been developed, each with its own
contrast agents and imaging equipment: methods based
on ultrasonic vibrations, radioactive substances (including
positron emission tomography, PET), magnetic resonance
imaging (MRI), and fluorescent substances. Each has its
own possibilities for applications and its own restrictions
[46]. Imaging that focuses on molecular biomarkers makes
early detection of diseases possible and provides information
on appropriate therapies. Imaging is also very suitable for
monitoring, evaluating and optimising treatment, that is,
being provided [16]. Nanotechnologies offer numerous pos-
sibilities for improving existing and designing new imaging
techniques [47–49].
Nanoparticles of perfluorohydrocarbons combined with
a lipid layer have multiple uses. They are suitable as an
ultrasonic contrast agent [50]. If gadolinium compounds or
radioactive substances such as technetium-99 are combined
with the lipid layer of the nanoparticles, they are also
suitable for MRI, or scintigraphic imaging [51]. Given the
right targeting molecule, the particles can make pathogenic
changes in blood vessels visible. The nanoparticles are
currently being studied for use as a contrast agent for
the diagnosis of atherosclerosis, thrombosis, and (tumour)
angiogenesis. A clinical study is expected to start within a few
years [48].
Superparamagnetic nanoparticles of iron oxide are now
being used clinically as an MRI contrast agent [52]. They
accumulate after intravenous administration in the liver, the
spleen, and the lymph glands, thereby enabling studies of
those organs [53]. Patient-based research has indicated that
they can also increase detectability of tumour metastases in
lymph glands [54]. Combined with dendrimers (Figure 3),
the particles can be used for marking living cells. Magne-
todendrimers of this kind make it possible to, for example,
monitor the migration and division of transplanted cells
in the body. The method, which has already been used
successfully on laboratory animals [55], may prove to be
of valuable assistance in the future in stem cell therapy.
Gadolinium dendrimers are also being developed for use
as contrast agents [56]. The first of these agents are almost
ready for introduction on the market [17]. Depending on
their size and solubility in water or fat, they are suitable
for examining blood vessels, kidneys, liver, or lymph glands
[57, 58].
Optical imaging techniques use fluorescent colouring
agents which are taken orally or injected and then accumulate
in a tumour, for example. The tumour cells fluoresce when
irradiated with laser light. Because the laser light cannot
penetrate deep into the body, this technique can only be used
for imaging tumours in or just below the skin or in tissue,
that is, accessible using an endoscope [5, 59].
Intensive research has been underway for several years
now into new optical methods based on the use of
nanoparticles. Quantum dots are at the most advanced stage
(Figure 4) of development [60–63]. These nanocrystals have
the advantage over colouring agents that they fade less
quickly over time and do not react with cell components.
Moreover, quantum dots of different colours can be made
to fluoresce with laser light of the same wavelength, which
makes multiplex applications possible. Nanoparticles have
already been successfully used in cell cultures and laboratory
animals to colour biomarkers on the surface of cancer cells
[64], to monitor the development of cell lines in a frog
embryo [65], and to make blood vessels visible in mice [66]
as well as lymph glands in pigs [67]. The hope is that the
latter application will in due course improve the possibilities
for tracing tumour metastases [66]. All these applications are
based on the fact that nanomaterials because of their minute
size can easily enter even the smallest compartment of the cell
[68].
The quantum dots are provided with a layer of lipids
or polymers, to prevent heavy metals from being released.
However, before clinical applications can be considered,
research will have to show that coatings of this sort are
also effective in the long term [63]. Contrast agents can
sometimes also act as a medicine. For example, under
the influence of laser light of a certain wavelength and in
the presence of oxygen, some fluorescent colouring agents
produce toxic substances which can destroy tumour cells by
oxidation. In addition, it is theoretically possible to combine
diagnosis and therapy by providing nanoparticles not only
with targeting molecules and contrast agents but also with
active substances. The nanoparticle then also acts as a drug-
delivery system.
4. Therapy
4.1. Drug Delivery. Many substances that could, in theory, be
used as medicines have the disadvantage that they are hardly,
if at all, able to reach the diseased organs or tissues in the
body. There are various possible reasons for this:
(1) the substance is hardly, if at all, soluble in water;
(2) the substance is broken down in the body or inacti-
vated before it reaches its target;
(3) the substance is hardly, if at all, capable of passing
certain biological barriers (cell membranes, placenta,
blood-brain barrier);
(4) the substance distributes nonspecifically to all kinds
of tissues and organs.
Substances of this kind are, therefore, ineffective or lead to
undesirable adverse side effects. As long as a hundred years
ago, German microbiologist Paul Ehrlich conceived of the
idea of using “magic bullets” to direct medicines at their
target more effectively [48]. This idea was taken up again
at the end of the 1960s and researchers have since been
developing such drug delivery systems [69]. Their miniscule
dimensions mean that all kinds of nanoparticles are suitable
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Figure 4: Single stranded DNA and quantum dot as building blocks for the construction of complex 3-dimensional structures which can be
used for biosensors. (Source: Schmid et al., Nanotechnology assesments and prospective, 2006, Springer).
for use in systems of this kind [48, 70–73]. Depending on the
type of particle, the active substance can be encapsulated or
attached to the surface. This means that even if they dissolve
poorly in water, they can be transported in an aqueous
solution, such as blood, and are better protected against
degradation by enzymes, for example. A suitable coating on
the nanoparticle can prevent identification and removal by
the immune system [74–76].
Selective accumulation in the target organ or tissue can
arise through various mechanisms [68]. The first mecha-
nism is passive. An example of this would be to use the
high permeability of the walls of blood vessels and the
reduced lymph drainage in tumour tissue [77]. However,
it is also possible to provide nanoparticles with “targeting
molecules” (e.g., specific antibodies or folic acid), which
ensure that the delivery system primarily bonds to the
diseased tissue (Figure 5). However, this can aid detection
by the immune system [78]. When provided with suitable
targeting molecules, some nanoparticles are able to transport
medicines across the blood-brain barrier to treat brain
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Schematic showing nanotube bundles bioconjugated with EGF
targeting the cell surface receptor EGFR on the cancer cell on
one side and with quantum dot (for imaging) or drug molecule
(for delivery) on other side. (Modified figure; original source:
Bhirde et al., ACS Nano, 2009, doi: 10.1021/nn800551s).
tumours, for example [79, 80]. The cells being treated
can then take up the delivery system containing the active
substance by means of endocytosis.
Combining the delivery systems with contrast agents,
fluorescent, or radioactive substances also makes it possible
to use imaging techniques to monitor how successful the
selective transport to the destination has been [81, 82]. Once
it has reached the target area, the active substance has to be
released from the carrier at the correct rate. This can occur
spontaneously by gradual diffusion, in combination with the
delivery system’s degradation or otherwise. It may also occur
as a result of special conditions at the destination, such as a
different acidity level [83], salt concentration, temperature,
or the presence of certain enzymes. The accumulation of the
delivery system and/or the release of the active substance
at the right place can also be controlled from outside by
influencing conditions in the target organ or tissue by means
of magnetic fields [84–86], near-infrared radiation [87],
ultrasonic vibrations [88], or heat [89–91]. The delivery
system used and the external treatment have to be precisely
matched to each other for this purpose.
The requirements that delivery systems have to fulfill are
as follows:
(1) their residence time in the blood must be long
enough to enable accumulation in the target tissue;
(2) they must be capable of containing sufficient active
substance;
(3) the systems or their degradation products must have
a favourable toxicity profile;
(4) they must have a shelf life long enough to allow
storage and distribution;
(5) the effectiveness must be in proportion to the costs.
Research into the suitability of a large variety of nanoparticles
for use as a delivery system is currently underway [48, 70–
73]. Which particles are most suitable depends on the active
substance that has to be transported, the target organ, and
the method of administration (oral, inhalation, dermal, by
injection). Some particles, such as nanoparticles of polymer
or of solid fat, appear to be usable for transporting a wide
range of substances. The scope for using other, especially
inorganic, nanoparticles is smaller. Most delivery systems
are currently being developed for transporting antitumour
agents, genetic material (gene therapy), as well as proteins
and peptides. Nanoparticles of polymers as delivery systems
for active substances have been taking place since the mid-
1970s. The usefulness of other systems, such as nanoparticles
of solid fat, dendrimers, fullerenes, and nanocrystals of the
active substance, only began to be studied in the early or
mid-1990s. There are now various medicines with delivery
systems on the market and many are in the clinical study
phase [69]. Magnetic nanoparticles stand first in this classifi-
cation. The idea of using magnetic micro- and nanoparticles
can be traced back to late 1970s. The work by Widder
et al. (1978, 1979) [92, 93] employedmagnetically responsive
microspheres to deliver antitumor drugs. Since the time of
these studies, numbers of groups have demonstrated the
efficacy of this approach in numerous small animal studies
[94, 95]. Although magnetic targeting has been successful in
a number of such studies, there remain only a small number
of clinical trials to date. The first phase I clinical trial of
magnetically targeted drug delivery was performed by Lubbe
et al. in 1996 [84]. In this study, epirubicine was complexed
to nanoparticles on the basis of electrostatic interactions
between phosphate groups bound to the surface of particles
and amino sugars present within the drug. Similarly, few
more clinical trials have been performed with promising
results [96, 97], thus promoting magnetic nanoparticles as
another tool for treatment of variety of diseases.
The future for drug delivery systems is expected to be
bright, even if significant obstacles still have to be overcome
[69]. Obstacles include the development of methods to
increase the specificity of delivery systems for target cells,
to more precisely regulate the bioavailability of active
substances in the target tissue, and to get active substances
to the destination within the cell more efficiently.
4.2. Nanoparticles as Medicines. Besides acting as a delivery
system, in some cases nanoparticles can act as an active
substance. Once they have found their way through the
bloodstream into a tumour, or have been injected directly
into it, metal-containing nanoparticles can be heated using
near-infrared radiation [98, 99] or a rapidly oscillating
magnetic field [100] so that the tumour cells die. As yet,
this relates to research conducted using laboratory animals. It
may also be possible to use single-wall carbon nanotubes in
a similar way [101, 102]. In vitro studies have in fact shown
that if combined with folic acid as targeting molecules, the
tubes are selectively taken up by cancer cells. These cells can
then be killed by using near-infrared radiation to heat the
tubes (Figure 5). Healthy cells appeared to take up few, if
any, nanotubes and not to be affected by the near-infrared
radiation [103].
Journal of Nanotechnology 7
Similarly, the temperature enhancement which occurs in
a magnetic nanoparticle (MNP) system under the influence
of an external high frequency magnetic field has found
application in cancer therapy by hyperthermia [104, 105]. In
magnetically mediated hyperthermia, one deposits magnetic
material in the tumour which is heated by the means of
an external alternating magnetic field. Beside the applica-
tion of macroscopic magnetic implants “seeds” which are
currently in clinical use for special cancer types, recent
studies are focused on magnetic nanoparticles as their heat
generation potential appears beneficial and they provide
the opportunity of direct tumour targeting through blood
circulation [106]. Beside the opportunity of a very localized
heat generation, the application of magnetic nanoparticles
offers the possibility of a self-limitation of the temperature
enhancement by using a magnetic material with suitable
Curie temperature [107]. In all cases, it is advantageous
to achieve the temperature enhancement needed for a
special application with as low as possible amount of MNP.
This is particularly important for applications where target
concentration is very low, for instance, in antibody targeting
of tumours.
Recent in vitro and in vivo studies have revealed that
silver nanoparticles are endowed with innate antiplatelet
properties [108], thus indicating their potential as future
antithrombotic drugs. Further studies are already underway
to characterize the fibrinolytic behavior of these nanomate-
rials in various pathological conditions like diabeties, stroke,
and myocardial infarction (S. Shrivastava et al., unpublished
data).
4.3. Passive Implants and Tissue Engineering. Artificial joints,
such as artificial hips, normally have a life of around ten to
fifteen years, after which complications occur, such as wear
or implant loosening, and further operations are required
[109]. Nanotechnologies could help reduce these problems.
The implants, which are usually made of titanium or alloys
of cobalt and chromium, can be provided with a thin layer
of a nanocrystalline structure, which is harder and smoother
and consequently more resistant to wear. This would also
result in less wear of the artificial socket, which is generally
made of a special type of polyethylene. Moreover, the layer
would ensure that the body better tolerates the implant
(better biocompatibility). The suitability of various materials
for use as a coating is currently being studied: diamond,
metal ceramic, and hydroxyapatite [110]. The latter material
is a natural component of bone, 70% of which consists
of the mineral hydroxyapatite, with the remaining 30%
consisting of organic fibres (collagen). Hydroxyapatite has
been used as a coating in implants for some time but
new production methods now make it possible to apply
layers with a grain size in the nanometre, rather than the
micrometre scale. This makes their structure more like that
of natural hydroxyapatite in bone, which likewise has a
nanocrystalline structure (grain size less than 50 nm). This
aids biocompatibility. The layer can even encourage the
growth and bonding of the surrounding bony tissue. In vitro
research has shown that bone-forming cells (osteoblasts)
adhere better and deposit more calcium on materials with
a grain size in the nanometre range than on conventional
materials with a grain size in the micrometre range [110–
113]. This is presumably related to the higher absorption of
proteins that stimulate cell adhesion [114]. Bone resorbent
cells (osteoclasts) also function better on these nanomate-
rials. Proper, coordinated function of both types of cells
is essential for the formation and maintenance of healthy
bony tissue and, therefore, for strong bonding between
the implant and the surrounding bone [109, 115, 116].
This is extremely important for implants that are attached
without the use of bone cement. Implants provided with
a hydroxyapatite layer with a nanostructure are currently
being tested in patients, in 2000, a patient in the Maastricht
University Hospital was the first to receive an artificial hip
with such a coating. Nanoparticles of hydroxyapatite can
also be introduced directly into damaged bones to accelerate
the repair of bony tissue. In recent years, a few medicines
have been admitted that work according to this principle.
Implant coatings with a nanostructure based on diamond
and metalceramic are still at the research stage. Their main
benefits are hardness, smoothness, corrosion resistance, and
good bonding to the implant [110].
The mechanical properties and biocompatibility of
implants can also be improved by providing the material
which is used to make the implants with a nanostructure.
This is possible by applying a thin layer of titanium dioxide
with nanopores. An added advantage of this approach is
that the layer can be made in a way that metal ions with
an antiseptic effect, such as copper ions, are slowly released.
This reduces the likelihood of bacterial infections, which
are a frequent complication with implants [117]. Another
possibility is to make the implants from nanopowders of
titanium dioxide or aluminium oxide using a sinter process.
Promising alternative materials include organic polymers
with a nanostructure and composite materials of organic
polymers into which nanofibres of carbon or nanoparticles
of titanium, aluminium, or hydroxyapatite have been mixed
[109, 118, 119]. The advantage of the organic polymers
is that they dissolve gradually while new bony tissue is
being formed. Studies are also underway of the possibilities
of generating bone with the help of scaffolds of carbon
nanotubes [120].
The orthopaedic applications are closest to being used
on patients [109], but biodegradable scaffolds of nanofibres
consisting of natural or synthetic organic polymers are
already used to cultivate other tissues, such as cartilage,
muscle tissue, nerve tissue, and vascular tissue in vitro [121].
Here too, the goal of the nanostructure is to imitate the
natural extracellular matrix. Researchers recently succeeded
in using nanofibres to regenerate brain tissue in vivo. Young
and adult hamsters, which had been blinded as a result of
intentionally caused brain damage, had their sight restored
within a few weeks of scaffold-forming nanomaterial being
injected into the brain [122]. It may also be possible to use
the method in the future to repair damaged human nerve
tissue. Stents are a completely different type of implant. They
are small tubes of woven thread used to dilate blood vessels.
Inflammatory reactions often occur and lead to the blood
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Figure 6: Schematic showing interaction of silver nanoparticles (AgNps) with protein leading to the formation of protein encapsulated
bioconjugate.
vessel closing again. This problem is dealt with using stents
with a coating of aluminium oxide which is provided with
nanopores. A radioactive substance can be applied to them,
which prevents the stent from clogging. The pores ensure
that sufficient radioactive material can be introduced and
that it is released very gradually. The functionality and safety
of these stents still have to be confirmed in animal trials.
Research is also underway into the possibility of using the
lotus effect: a coating of titanium compounds is used to
prevent clotting reactions owing to conformation changes in
proteins in the blood caused by their contact with the stent
wall [123].
4.4. Active Implants. Active implants are implants that
contain a source of energy. They can be divided into two
groups on the basis of their function. The first category
comprises implants for administering medicines, such as
insulin pumps and morphine pumps. They have been in
use for a long time. Work has also been underway for
several years on implantable microchips for the storage
and controlled release of active substances [124, 125]. The
benefits of this approach to administering medicines include
the fact that the medicines go directly to the location where
they are needed and can, if required, be administered at
varying rates. The release could also be controlled by a
biosensor that responds to physiological parameters. The
first system of this kind is soon due to be tested on patients
[126].
The second group comprises neural prostheses, which
are intended to repair or take over nerve functions. For
instance, they bridge damaged nerve paths, provide impulses
for muscles or replace senses. This category includes cochlear
implants (for restoring hearing), pacemakers and defibrilla-
tors (for regulating the heart beat), bladder stimulators (for
controlled emptying of the urinary bladder by spinal cord
lesion patients), deep-brain stimulators (to combat tremor
in patients with Parkinson’s disease), as well as peroneus
stimulators (to combat drop foot).
These are all currently used in patients and some have
been in use for decades. On the other hand, retinal implants
to restore the sight in patients with a damaged retina
are still in development. In recent years, a great deal of
research has been conducted into this in the United States,
Germany, and Japan. Although considerable advances are
being made and the first clinical tests are already underway,
some major obstacles still have to be overcome. It will
probably be years before “artificial retinas” are as common as
the other neural implants [127]. For some years now, various
research groups in the United States have also been working
on neuroprostheses that enable devices to be operated by
thought [128–133]. To this end, one or more chips with
electrodes are fitted to the motor cerebral cortex, which
register the electrical signals associated with thoughts. These
prostheses are also referred to as brain-machine interfaces.
They have now succeeded in enabling rats to operate handles
by “brain power” and monkeys to operate the cursor of a
computer or a robot arm [130, 131]. A few years ago, an
amyotrophic lateral sclerosis (ALS) patient had an electrode
implanted in the cerebral cortex to enable him to operate
a computer [134]. In 2004, a neuroprosthesis was fitted to
a paralysed man. It enables him to operate the cursor of
a computer by thought, play video games, operate a light
switch, and select a television channel. The findings were
presented at the annual meeting of the American Academy
of Physical Medicine and Rehabilitation, in Phoenix in
October 2004 [135]. The ultimate goal, which is still far-
off, is to enable patients to operate arm or leg prostheses
or even to restore their control of their paralysed limbs
[129, 132].
Conversely, it also proved possible to control rats
remotely by administering electrical stimuli in the parts of
the brain involved in touch and in experiencing pleasant
feelings [136, 137]. These so-called “robotrats” could be used
to search for victims underneath the rubble of collapsed
houses, to detect landmines, or to be used as mobile
biosensors. All these active implants are essential products of
microtechnologies but nanotechnologies may play an impor-
tant role in their improvement and further development.
Research is mainly concerned with increasing functionality,
fixation in the surrounding tissue, and biocompatibility by
modifying the surface at the nanoscale [138]. For example,
electrodes with a nanoporous surface are being developed for
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retinal implants. This nanostructure increases the electrodes’
surface area by a factor of one hundred, which is necessary for
proper signal transfer from the electrodes to the tissue [139].
The microelectrodes of neuroprostheses that register electri-
cal signals in the brain often only work for a few weeks. They
do not usually become defective but the surrounding tissue
gets damaged and nonconductive scar glial-cell tissue grows.
In vitro research has shown that a nanoporous surface struc-
ture reduces glial-cell adhesion and promotes the formation
of outgrowths of nerve cells [140]. A possible explanation
for the stimulating effect on the nerve cells is that they are
naturally embedded in an extracellular matrix with a nanos-
tructure of microtubuli and laminin. To combat rejection
reactions or infections, coatings can be applied that release
medicines gradually [141]. An antiseptic layer based on silver
nanoparticles is already being used in Germany on cochlear
implants [142]. Other examples of contributions made by
nanotechnologies to active implants include the membranes
with nanopores in microchips for drug delivery [143] and
batteries with a higher energy-storage capacity [144].
5. Other Applications
5.1. Disinfection. The disinfectant effect of silver has long
been known but the use of silver in combating pathogenic
microorganisms decreased with the emergence of organic
antibiotics. The increasing resistance of bacteria to antibi-
otics has resulted in renewed interest in silver as a disinfec-
tant. The antiseptic effect is based on silver ions [145]. They
block the enzymes required for oxygen metabolism, desta-
bilise the cell membrane, and block cell division. Bacteria
are not expected to develop resistance to silver, owing to
the diversity of the working mechanisms. Especially in the
form of nanoparticles, silver is extremely effective thanks to
the large contact area with the environment [10]. Moreover,
the particles have the advantage that they can be readily
integrated with other materials like (Figure 6) globular or
fibrous proteins (communicated data) and polymers [146].
The nanoparticles then act as depots that continually release
new silver ions [147]. When applied to medical instruments
or implants, antimicrobial layers of this kind can help reduce
the number of infections. Current research is studying uses
on catheters, cochlear implants and in bone cement [148–
150]. Antimicrobial wound dressings containing nanocrys-
talline silver are already on the market [151].
Titanium dioxide nanoparticles also have a bactericidal
effect. This is based on a photocatalytic effect. Under the
influence of ultraviolet radiation and in the presence of water
and oxygen, the particles form extremely reactive molecules
(radicals), such as hydroxyl and perhydroxyl radicals, which
kill microorganisms [152]. Titanium dioxide can be used to
produce antiseptic surfaces that only work in the presence of
UV radiation. Fullerenes also have an antimicrobial effect in
the presence of light [153]. Various antimicrobial products
based on nanoparticles are already on the market [154].
5.2. Identification, Security, and Logistics. Radio Frequency
Identification labels (RFID labels) consist of a microchip to
which a radio antenna is attached. The chip can contain
information on a product that contains it or to which it is
attached. A scanning device can activate the chip by means
of the antenna, which in turn transmits the information
stored in the chip. The labels are used for identification
and security purposes and for following flows of goods.
They have been in use for some time, for locating stolen
cars and bicycles, for example, and for identifying domestic
pets and cattle. The labels are a product of microtechnology
but nanotechnologies offer possibilities for making them
smaller and cheaper. This is expected to increase their use
considerably. RFID labels are already used in hospitals and
care institutions. They are used to prevent newborns from
being abducted or confused or demented patients from
wandering away unnoticed [155]. They are also increasingly
being used for identifying patients or samples taken from
patients, alongside or instead of labels with bar codes [155,
156]. This is to enable an early response when the wrong
patient is taken to an operating room, for example [157].
They are also expected to reduce the number of wrong blood
transfusions [158]. The labels can also simplify the tracing
and localisation of expensive hospital equipment, making
it easier to trace medicines and to help in combating drug
counterfeiting [155]. Implanting RFID labels in victims of
disasters can facilitate their subsequent identification [159].
Meanwhile, RFID labels the size of a grain of rice are
available for implantation under the skin. The Food and
Drug Administration in the United States approved a label
of this kind in 2004. A person’s medical record can be stored
on the chip. The idea behind this is that faster availability
of the right medical information could save a person’s life
in an emergency. Apart from health care, these kinds of
chips are also finding important role in agriculture and food
technologies [160].
6. Summary
The multidisciplinary field of nanotechnology’s application
for discovering new molecules and manipulating those
available naturally could be dazzling in its potential to
improve health care. The spin-offs of nanobiotechnology
could be utilised across all the countries of the world.
In the future, we could imagine a world where medical
nanodevices are routinely implanted or even injected into
the bloodstream to monitor health and to automatically
participate in the repair of systems that deviate from the
normal pattern. The continued advancement in the field
of biomedical nanotechnology is the establishment and
collaboration of research groups in complementary fields.
Such collaborations have to be maintained not only on
specialty field level but also internationally. The successful
development and implementation of international collabo-
rations fosters a global perspective on research and brings
together the benefits to mankind in general. However, nan-
otechnology in medicine faces enormous technical hurdles
in that long delays and numerous failures are inevitable.
This is because the effort needed to produce nanoscale
biomedical or therapeutic devices is highly interdisciplinary.
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As we have seen, it touches on numerous established disci-
plines, encompassing elements of physiology, biotechnology,
chemistry, electrical engineering, and materials science, to
name just a few of the fields involved. Obviously, this broad
sweep of knowledge is difficult for any one investigator
to master fully. The breadth of the effort constitutes just
one of the major barriers to entry in the field. Other
challenges include inadequate funding, the raw complexity of
biology, the fashion in which biologists hold and distribute
information, and cultural differences between engineers
and biological scientists. Likewise, it should not be taken
for granted the dangers and negative consequences of
nanobiotechnology when applied in warfare, in the hands
of terrorists and disasters associated with its application in
energy generation when and wherever it strikes, or the risks
associated with nanoparticles in blood circulation. It should
be appreciated that nanotechnology is not in itself a single
emerging scientific discipline but rather a meeting point
of traditional sciences like chemistry, physics, biology, and
materials science to bring together the required collective
knowledge and expertise required for the development of
these novel technologies.
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